openPR Logo
Press release

Global Biosimilar Monoclonal Antibodies Market: Trend Analysis and Forecast to 2022

02-20-2017 11:24 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Na

/ PR Agency: NA
Biosimilar Monoclonal Antibodies Market

Biosimilar Monoclonal Antibodies Market

The Biosimilar Monoclonal Antibodies Market is driven by rituximab and infliximab submarkets, the rituximab submarket is accounted as the highest holding market share submarket and the infliximab submarket will become the leading submarket by 2018 continuing its dominance until 2022. A monoclonal antibody is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. A monoclonal antibody is made so that it binds to only one substance to treat different types of cancer. There are several types of monoclonal antibodies that are being used to treat certain types of cancer. Laboratory production of monoclonal antibodies is produced from clones of only one cell which means that every monoclonal antibody produced by the cell is the same due to which they are called as biosimilar monoclonal antibodies. Each monoclonal antibody recognizes one particular protein. They work in different ways depending on the protein they are targeting, hence different monoclonal antibodies are required to be made to target different types of cancers.

In 2014, the size of the global biosimilar monoclonal antibodies market was valued over USD 352 million. While in 2015, the market size reached to USD xxx.x million. The global biosimilar monoclonal antibodies market is projected to grow with a CAGR between 42.9% and 43.5% during 2016-2022 and reach USD xxxx.x million by 2022. Patient expiration of biologics, innovative product in the pipeline and increasing healthcare infrastructure are expected to be key factors driving the growth of global biosimilar monoclonal antibodies market. However, unfavorable government regulations and development policies, undesirable manufacturing process and cost structure associated with the manufacturing process are considered to be restraining factors in the global biosimilar monoclonal antibodies market. Furthermore, increasing demand for cost effective treatment, collaboration with the local players and high profitability in the market are the key opportunities for the companies to invest in the biosimilar monoclonal antibodies market.

Segments Covered:

The report segments the global biosimilar monoclonal antibodies market by drug class and by application.The market segmentation based on drug class includes, rituximab, infliximab, abciximab, trastuzumab, adalimumab, and bevacizumab. Moreover, based on application the biosimilar monoclonal antibodies market is segmented into oncology, chronic and auto immune diseases, growth hormone deficiency and infectious diseases.

Geographic Coverage and Analysis:

The report provides regional analysis covering geographies such as North America, Europe, Asia Pacific, Latin America, and Rest of the World (RoW). Europe is the largest biosimilar monoclonal antibodies market globally. Due to favorable regulatory policies designed by the European Medical Association (EMA) and since Europe was the first region to draft guidelines for approval of biosimilar products, the European market has a largest these market share on the market. Asia pacific is expected to grow at the highest CAGR over the forecast period and provides the opportunity to market growth due to increasing demand of cost effective treatment to the prevalence of chronic diseases and launch of new biosimilar monoclonal antibodies. Nevertheless, government investment in healthcare will also act as a growth opportunity for biosimilar monoclonal antibodies market in the Asia-Pacific region.

Companies Profiled:

The companies covered in the report include

Pfizer Inc
Novartis AG
Reliance Life Sciences
Allergan plc
Coherus BioSciences Inc
Biocon
Dr. Reddy’s Laboratories Ltd.
Boehringer Ingelheim GmbH
BioXpress Therapeutics SA
Intas Pharmaceuticals Limited
BIOCAD
Genor BioPharma Co. Ltd
Celltrion Inc

Infinium Global Research and Consulting Solutions is started with a single motto of being business partner of first choice. We at Infinium work on the strengths of our clients to ensure we help them consolidate their market position. We firmly believe in the fact that ‘if you are able to develop newer opportunities then you find there is no dearth of opportunities for you’. With our strategic research approaches and deep dive in the market segments, we try to find out new opportunities that our clients can encash with their existing resources. Our experts with over 100 years of cumulative experience in research offer the best in the industry services to our clients to ensure that they achieve their business goals.

Infinium Global Research
16, Royal Arcade, Near Pune IT Park, Bhau Patil Road, Bopodi, Pune
1-800-638-0796(US)/44-2033182010(UK)
Email: sales@infiniumglobalresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Biosimilar Monoclonal Antibodies Market: Trend Analysis and Forecast to 2022 here

News-ID: 442074 • Views: 248

More Releases from Na

Global Food Packaging Market: Trends Analysis & Forecasts up to 2022
Food Packaging Market is an effective method for containing food and for protecting food against contamination caused due to factors such as biological, chemical, environmental and physical. Packaging helps in preserving the food during the journey from factory to the end user in the distribution chain. It increases the shelf life of the food products. Flexible packaging is the largest type of packaging used in the food packaging market
Global Food Safety Testing Market: Trends Analysis & Forecasts up to 2022
Presence of contaminants or chemicals in canned foods, farm fresh foods frozen foods and processed foods can lead to food poisoning or other adverse effects on human health. The harmful materials or pathogens could enter the value chain at any point from source to final delivery to the customers. Therefore, it is important to conduct various tests to ascertain the food safety during the manufacturing phase and before the food
Global Food Encapsulation Market: Trends Analysis & Forecasts up to 2022
Food Encapsulation is an important tool for improving the delivery of bioactive molecules and living cells in food ingredients. Food encapsulation helps in increasing the shelf life, maintaining color, taste as flavor of processed foods. It is widely used in industries such as beer, beverages, confectionary, diary, meat, poultry, wine and others. Vitamins and additives have higher share in encapsulation market as they are widely consumed in functional foods. Among
Global Dehydrated backpacking and camping food Market: Trends Analysis & Forecas …
The Dehydrated backpacking and camping food Market is anticipated to grow significantly due to rising number of camping enthusiasts. backpacking and camping food is used by trekkers and people who go on camping. The dehydrated meal is designed to provide the energy to the trekkers and campaigners. The companies that manufacture dehydrated backpacking and camping food, pay a special attention to the energy content of the food. With growing work-life

All 5 Releases


More Releases for Biosimilar

Global Biosimilar Drug Sales Market Report 2018
In this report, the global Biosimilar Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Free | Request Sample Copy of the Report @ https://bit.ly/2M8e47Z Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Biosimilar Drug for
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight
“Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Herceptin are commercially available in India and Iran for the treatment of Breast cancer. The patent on Herceptin expired in 2014. Trastuzumab or
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.